Indivior PLC (NASDAQ:INDV) Plans $8.13 Special Dividend

Indivior PLC (NASDAQ:INDV – Get Free Report) announced a special dividend on Thursday, September 17th. Investors of record on Friday, October 30th will be paid a dividend of 8.13 per share on Friday, November 6th. The ex-dividend date of this dividend is Friday, October 30th.

Indivior Trading Up 3.9%

Shares of NASDAQ INDV traded up $1.34 during trading hours on Thursday, reaching $35.69. The stock had a trading volume of 1,680,788 shares, compared to its average volume of 2,180,127. The firm has a 50-day moving average of $37.81 and a 200-day moving average of $36.08. The firm has a market cap of $4.21 billion, a price-to-earnings ratio of 12.79 and a beta of 0.82. Indivior has a fifty-two week low of $22.22 and a fifty-two week high of $42.81.

Get Indivior alerts:

Indivior (NASDAQ:INDV – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The business had revenue of $343.00 million for the quarter. On average, equities analysts predict that Indivior will post 3.66 EPS for the current year.

Insider Transactions at Indivior

In other news, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the transaction, the insider owned 209,337 shares of the company’s stock, valued at $8,612,124.18. This represents a 8.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson purchased 1,500 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were bought at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares during the period. Rockefeller Capital Management L.P. raised its holdings in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares during the period. TD Waterhouse Canada Inc. purchased a new position in shares of Indivior in the 2nd quarter worth about $63,000. GAMMA Investing LLC acquired a new position in shares of Indivior in the 2nd quarter valued at about $66,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Indivior in the 4th quarter valued at about $155,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

(Get Free Report)

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.

See Also

• Five stocks we like better than Indivior
• Aeluma’s Selloff Could Be Setting Up Its Next Big Move
• Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
• The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.